BACKGROUND: Treatment options for metastatic renal cell carcinoma (mRCC) are rapidly expanding, and immunotherapy using checkpoint inhibitors is a first- or second-line option for most patients. OBJECTIVE: The objective of the present retrospective analysis was to explore the real-world impact of checkpoint inhibitor-based immunotherapy compared with therapy using other types of targeted therapies using a large real-world database. METHODS: RenIS, a registry of patients with mRCC was used as a data source. Outcomes were compared for cohorts treated with TKIs or mTOR inhibitors only [targeted therapy (TT) cohort] versus patients who received immunotherapy (IO) using a checkpoint inhibitor in any line of treatment (IO cohort). Data from a total of 1981 patients were extracted from the registry, including 1767 patients in the TT cohort and 214 patients in the IO cohort. RESULTS: The median overall survival from the initiation of first-line treatment was 24.5 months versus not reached (p < 0.001) in the TT cohort versus the IO cohort, respectively [HR 0.23, 95% CI (0.17-0.31), p < 0.001]. The probability of 5-year survival was 24.2 versus 67.9% in the TT cohort versus the IO cohort, respectively. Immunotherapy in any line of treatment was associated with a lower risk of death. Overall survival was superior for patients receiving immunotherapy as the first or second treatment line compared with patients treated with non-immunological targeted therapy. CONCLUSION: In real-world patients with mRCC, immunotherapy is associated with significant survival benefit. The present retrospective analysis shows the real-world benefit of second-line immunotherapy in patients previously treated with tyrosine-kinase inhibitors.

Department of Comprehensive Cancer Care and Faculty of Medicine Masaryk Memorial Cancer Institute and Masaryk University Brno Czech Republic

Department of Oncology 1st Faculty of Medicine Charles University and Thomayer University Hospital Prague Czech Republic

Department of Oncology 2nd Faculty of Medicine Charles University and Motol University Hospital 5 Uvalu 84 150 06 Prague Czech Republic

Department of Oncology and Radiotherapy Faculty of Medicine and University Hospital in Pilsen Charles University Pilsen Czech Republic

Department of Oncology Liberec Regional Hospital Liberec Czech Republic

Department of Oncology Palacky University Medical School and Teaching Hospital Olomouc Czech Republic

Department of Urologic Oncology Masaryk Memorial Cancer Institute and Masaryk University Brno Czech Republic

Faculty of Medicine in Pilsen Biomedical Centre Charles University Pilsen Czech Republic

Institute of Biostatistics and Analyses Brno Brno Czech Republic

University Hospital in Hradec Králové Hradec Králové Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc24000768

003      

CZ-PrNML

005      

20240213093351.0

007      

ta

008      

240109s2023 fr f 000 0|eng||

009      

AR

024    7_

$a 10.1007/s11523-023-01013-0 $2 doi

035    __

$a (PubMed)37957520

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a fr

100    1_

$a Poprach, Alexandr $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic

245    10

$a Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma / $c A. Poprach, I. Kiss, M. Stanik, T. Barusova, L. Pospisilova, O. Fiala, J. Kopecky, I. Richter, B. Melichar, H. Studentova, R. Lakomy, M. Holanek, A. Rozsypalova, A. Zemanková, M. Svoboda, T. Buchler

520    9_

$a BACKGROUND: Treatment options for metastatic renal cell carcinoma (mRCC) are rapidly expanding, and immunotherapy using checkpoint inhibitors is a first- or second-line option for most patients. OBJECTIVE: The objective of the present retrospective analysis was to explore the real-world impact of checkpoint inhibitor-based immunotherapy compared with therapy using other types of targeted therapies using a large real-world database. METHODS: RenIS, a registry of patients with mRCC was used as a data source. Outcomes were compared for cohorts treated with TKIs or mTOR inhibitors only [targeted therapy (TT) cohort] versus patients who received immunotherapy (IO) using a checkpoint inhibitor in any line of treatment (IO cohort). Data from a total of 1981 patients were extracted from the registry, including 1767 patients in the TT cohort and 214 patients in the IO cohort. RESULTS: The median overall survival from the initiation of first-line treatment was 24.5 months versus not reached (p < 0.001) in the TT cohort versus the IO cohort, respectively [HR 0.23, 95% CI (0.17-0.31), p < 0.001]. The probability of 5-year survival was 24.2 versus 67.9% in the TT cohort versus the IO cohort, respectively. Immunotherapy in any line of treatment was associated with a lower risk of death. Overall survival was superior for patients receiving immunotherapy as the first or second treatment line compared with patients treated with non-immunological targeted therapy. CONCLUSION: In real-world patients with mRCC, immunotherapy is associated with significant survival benefit. The present retrospective analysis shows the real-world benefit of second-line immunotherapy in patients previously treated with tyrosine-kinase inhibitors.

650    _2

$a lidé $7 D006801

650    12

$a karcinom z renálních buněk $x farmakoterapie $7 D002292

650    12

$a nádory ledvin $x farmakoterapie $x patologie $7 D007680

650    _2

$a retrospektivní studie $7 D012189

650    _2

$a protokoly antitumorózní kombinované chemoterapie $7 D000971

650    _2

$a imunoterapie $7 D007167

655    _2

$a časopisecké články $7 D016428

700    1_

$a Kiss, Igor $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic

700    1_

$a Stanik, Michal $u Department of Urologic Oncology, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic

700    1_

$a Barusova, Tamara $u Institute of Biostatistics and Analyses Brno, Brno, Czech Republic

700    1_

$a Pospisilova, Lenka $u Institute of Biostatistics and Analyses Brno, Brno, Czech Republic

700    1_

$a Fiala, Ondrej $u Department of Oncology and Radiotherapy, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic $u Faculty of Medicine in Pilsen, Biomedical Centre, Charles University, Pilsen, Czech Republic

700    1_

$a Kopecky, Jindrich $u University Hospital in Hradec Králové, Hradec Králové, Czech Republic

700    1_

$a Richter, Igor $u Department of Oncology, Liberec Regional Hospital, Liberec, Czech Republic

700    1_

$a Melichar, Bohuslav $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic

700    1_

$a Studentova, Hana $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic

700    1_

$a Lakomy, Radek $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic

700    1_

$a Holanek, Milos $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic

700    1_

$a Rozsypalova, Aneta $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic

700    1_

$a Zemanková, Anezka $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic

700    1_

$a Svoboda, Marek $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic

700    1_

$a Buchler, Tomas $u Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, 150 06, Prague, Czech Republic. tomas.buchler@fnmotol.cz $1 https://orcid.org/000000016667994X $7 xx0096851

773    0_

$w MED00189571 $t Targeted oncology $x 1776-260X $g Roč. 18, č. 6 (2023), s. 893-903

856    41

$u https://pubmed.ncbi.nlm.nih.gov/37957520 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y - $z 0

990    __

$a 20240109 $b ABA008

991    __

$a 20240213093348 $b ABA008

999    __

$a ok $b bmc $g 2049410 $s 1210462

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2023 $b 18 $c 6 $d 893-903 $e 20231113 $i 1776-260X $m Targeted oncology $n Target Oncol $x MED00189571

GRA    __

$a NU21-03-00539 $p Ministerstvo Zdravotnictví Ceské Republiky

LZP    __

$a Pubmed-20240109